LUCIDITY

This final phase clinical study will test the drug’s effectiveness in delaying the progression of Alzheimer’s disease in volunteers aged 60-90, with mild to moderate memory loss and other symptoms of cognitive impairment

"*" indicates required fields

Step 1 of 3

Submit your interest to our team of specialists

First Name*

Last Name*

Email*

Phone Number*

Alzheimer’s disease is characterized by the excessive accumulation of amyloid and tau protein in the brain, which eventually leads to the destruction of healthy brain cells. This new study is designed to reduce the elevated levels of abnormal tau protein in the brain and thereby slow or, ideally, stop the further progression of the disease and its symptoms.

This is a randomized, placebo-controlled study which will comprise a 12-month double-blind phase; during which 2/3 of individuals will receive active medication and 1/3 placebo. This is followed by 12 months when all study participants receive the active medication.

Our team of brain and mind experts at Re:Cognition Health are passionate about helping to find effective treatments for Alzheimer’s and other neurodegenerative diseases. Clinical research is vital to finding new medical treatments, and testing for safety and efficacy; every single medication for every condition has to undergo rigorous testing before being made available to the market. According to the National Institute for Health Research, there were over 6,100 clinical studies ongoing in England in 2019, demonstrating the importance and scope of the work being carried out.

With every study conducted, we come closer to understanding more about Alzheimer’s disease, unlocking new treatments and ultimately finding a cure.

For further information on this clinical trial please fill in your details below or call us on our freephone number 0800 802 1030